---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-100527"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T22:02:13.659471+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# InMed publishes study on cannabinol anti-inflammatory effects in skin diseases

## Summary
- Study published in peer-reviewed journal Biofactors; sponsored by InMed and led by Dr. Maccarrone.
- CBN prevented keratinocyte inflammation via TRPV1 and modulated endocannabinoid system enzymes.
- CBN reduced pro-inflammatory cytokines (IL-8, IL-12, IL-31) and increased anti-inflammatory IL-10.
- Potential applications for psoriasis, atopic dermatitis, and pruritus; supports cosmetic and therapeutic use.

## SEC filing metadata
- accession: 0001213900-24-100527
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024100527/0001213900-24-100527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024100527/ea0222020-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-100527
- JSON: https://secwatch.observer/filing/0001213900-24-100527.json
- Plain text: https://secwatch.observer/filing/0001213900-24-100527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.